Previous Close | 1.2200 |
Open | 1.2400 |
Bid | 1.1100 x 4000 |
Ask | 1.8700 x 1300 |
Day's Range | 1.2000 - 1.2600 |
52 Week Range | 1.0300 - 17.7900 |
Volume | |
Avg. Volume | 134,472 |
Market Cap | 32.003M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Insiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more...
Toward the end of trading Friday, the Dow traded up 0.42% to 36,071.48 while the NASDAQ rose 0.84% to 15,835.89. The S&P also rose, gaining 0.61% to 4,677.60. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 47,693,510 cases with around 780,770 deaths. India confirmed a total of at least 34,414,180 cases and 462,690 deaths, while Brazil reported over 21,926,520 COVID-19 cases with 610,320 deaths. In total, there were at least 252,785,840 cases of
Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors. ONCR-177 is a Herpes Simplex Virus (HSV) product candidate. In the dose-escalation portion of the trial, ONCR-17 was well tolerated with no dose-limiting toxicities. 4x108 PFU in 4 mL was selected as the recommended Phase 2 dose (RP2D). With four evaluable patients in the monot